Evidence map›Paper›PMID 35666570›Full record

ArticleJMIR diabetes2022

Algorithm-Enabled, Personalized Glucose Management for Type 1 Diabetes at the Population Scale: Prospective Evaluation in Clinical Practice.

David Scheinker, Angela Gu, Joshua Grossman, Andrew Ward, Oseas Ayerdi, Daniel Miller, Jeannine Leverenz, Korey Hood, Ming Yeh Lee, David M Maahs and 1 more

Open access · goldAbstract read
In one paragraph

Article in JMIR diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Determinants, implementation strategies, and mechanisms of the 4T Program.Journal of clinical & translational endocrinology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Role and Perspective of Certified Diabetes Care and Education Specialists in the Development of the 4T Program.Diabetes spectrum : a publication of the American Diabetes Association · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. A New Technology-Enabled Care Model for Pediatric Type 1 Diabetes.NEJM catalyst innovations in care delivery · 2022
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

David ScheinkerDepartment of Pediatrics, Division of Pediatric Endocrinology, Stanford University, Stanford, CA, United States.ORCID https://orcid.org/0000-0001-5885-8024
Angela GuDepartment of Management Science and Engineering, Stanford University School of Engineering, Stanford, CA, United States.ORCID https://orcid.org/0000-0003-4513-4208
Joshua GrossmanDepartment of Management Science and Engineering, Stanford University School of Engineering, Stanford, CA, United States.ORCID https://orcid.org/0000-0001-5014-1336
Andrew WardDepartment of Management Science and Engineering, Stanford University School of Engineering, Stanford, CA, United States.ORCID https://orcid.org/0000-0002-4692-1126
Oseas AyerdiDepartment of Management Science and Engineering, Stanford University School of Engineering, Stanford, CA, United States.ORCID https://orcid.org/0000-0001-5692-9749
Daniel MillerDepartment of Management Science and Engineering, Stanford University School of Engineering, Stanford, CA, United States.ORCID https://orcid.org/0000-0003-0617-440X
Jeannine LeverenzLucile Packard Children's Hospital, Stanford University, Stanford, CA, United States.ORCID https://orcid.org/0000-0002-0603-2578
Korey HoodDepartment of Pediatrics, Division of Pediatric Endocrinology, Stanford University, Stanford, CA, United States.ORCID https://orcid.org/0000-0001-5730-7749
Ming Yeh LeeLucile Packard Children's Hospital, Stanford University, Stanford, CA, United States.ORCID https://orcid.org/0000-0001-8681-9073
David M MaahsDepartment of Pediatrics, Division of Pediatric Endocrinology, Stanford University, Stanford, CA, United States.ORCID https://orcid.org/0000-0002-4602-7909
Priya PrahaladDepartment of Pediatrics, Division of Pediatric Endocrinology, Stanford University, Stanford, CA, United States.ORCID https://orcid.org/0000-0002-3894-4344
Stanford University · USLucile Packard Children's Hospital · US

Funding

Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
Diabetes, Endocrinology and Metabolism Training GrantT32DK007217 · NIDDK · STANFORD UNIVERSITY · PI Justin Pierce Annes, David Matthew Maahs · 1987 to 2026
$7.2M
Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D: 4T StudyR18DK122422 · NIDDK · STANFORD UNIVERSITY · PI MAAHS, DAVID MATTHEW · 2020 to 2024
$3.2M
NIDDK NIH HHS P30 DK116074NIDDK NIH HHS R18 DK122422NIDDK NIH HHS T32 DK007217
6 · The paper itself

Abstract

backgroundThe use of continuous glucose monitors (CGMs) is recommended as the standard of care by the American Diabetes Association for individuals with type 1 diabetes (T1D). Few hardware-agnostic, open-source, whole-population tools are available to facilitate the use of CGM data by clinicians such as physicians and certified diabetes educators.

objectiveThis study aimed to develop a tool that identifies patients appropriate for contact using an asynchronous message through electronic medical records while minimizing the number of patients reviewed by a certified diabetes educator or physician using the tool.

methodsWe used consensus guidelines to develop timely interventions for diabetes excellence (TIDE), an open-source hardware-agnostic tool to analyze CGM data to identify patients with deteriorating glucose control by generating generic flags (eg, mean glucose [MG] >170 mg/dL) and personalized flags (eg, MG increased by >10 mg/dL). In a prospective 7-week study in a pediatric T1D clinic, we measured the sensitivity of TIDE in identifying patients appropriate for contact and the number of patients reviewed. We simulated measures of the workload generated by TIDE, including the average number of time in range (TIR) flags per patient per review period, on a convenience sample of eight external data sets, 6 from clinical trials and 2 donated by research foundations.

resultsOver the 7 weeks of evaluation, the clinical population increased from 56 to 64 patients. The mean sensitivity was 99% (242/245; SD 2.5%), and the mean reduction in the number of patients reviewed was 42.6% (182/427; SD 10.9%). The 8 external data sets contained 1365 patients with 30,017 weeks of data collected by 7 types of CGMs. The rates of generic and personalized TIR flags per patient per review period were, respectively, 0.15 and 0.12 in the data set with the lowest average MG (141 mg/dL) and 0.95 and 0.22 in the data set with the highest average MG (207 mg/dL).

conclusionsTIDE is an open-source hardware-agnostic tool for personalized analysis of CGM data at the clinical population scale. In a pediatric T1D clinic, TIDE identified 99% of patients appropriate for contact using an asynchronous message through electronic medical records while reducing the number of patients reviewed by certified diabetes care and education specialists by 43%. For each of the 8 external data sets, simulation of the use of TIDE produced fewer than 0.25 personalized TIR flags per patient per review period. The use of TIDE to support telemedicine-based T1D care may facilitate sensitive and efficient guideline-based population health management.

Indexed as

continuous glucose monitordiabetespersonalized medicinepopulation healthtelehealth

Identifiers

PMID35666570
PMCPMC9210201
OpenAlexW4213081336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.